

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SEN

03 AUG 14 PM 1:

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page


| | | | |
|--|----------------------------------|-------------------|----------------------------------|
| 1. Registrant Name GlaxoSmithKline | | | |
| 2. Address <input type="checkbox"/> Check if different than previously reported 1500 K Street, NW Suite 650 | | | |
| 3. Principal Place of Business (if different from line 2) City: Washington, DC State/Zip (or Country) 20005 | | | |
| 4. Contact Name Janie A. Kinney | Telephone 202-715-1000 | E-mail (optional) | 5. Senate ID# 16293-12 |
| 7. Client Name <input checked="" type="checkbox"/> Self | | | 6. House ID# 31461000 |

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying Activity **INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

| 12. Lobbying Firms | 13. Organization |
|--|--|
| INCOME relating to lobbying activities for this reporting period was: | EXPENSES relating to lobbying activities for this report were: |
| Less than \$10,000 <input type="checkbox"/> | Less than \$10,000 <input type="checkbox"/> |
| \$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000) | \$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>2,050,000</u> Expenses (nearest \$20,000) |
| Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of |
| | <input checked="" type="checkbox"/> Method A. Reporting amounts used LDA defini |
| | <input type="checkbox"/> Method B. Reporting amounts under section 60. of the Internal Revenue Code |
| | <input type="checkbox"/> Method C. Reporting amounts under section 16. Internal Revenue Code |

Signature



Date

August 13 2003

Printed Name and Title

Sarah J. Walsh , Vice President, Federal Government Relations Tax and Pharmaceuticals

LD-2 (REV. 6/98)

Page 1

Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

- S. 1225 Greater Access to Affordable Pharmaceuticals Act
- S. 54 Greater Access to Affordable Pharmaceuticals Act
- H.R. 2491 Greater Access to Affordable Pharmaceuticals Act

17. House(s) of congress and Federal agencies contacted Check if None


- U.S. House Of Representatives
- U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Janie A. Kinney | |
| Sarah J. Walsh | |
| Patrick McLain | |
| William Schuyler | |
| Elizabeth York | |
| Kimberly A. Williams | |
| Philip Thevenet | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature



Date

August 13, 2003

Printed Name and Title

Sarah J. Walsh , Vice President, Federal Government Relations, Tax and Pharmaceuticals

LD-2 (REV. 6/98)

Page 2 o

Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

HR 1, S.1 Prescription Drug & Medicare Improvement Act of 2003
 H.R. 2427 Pharmaceutical Market Act of 2003
 H.R. 847 To Amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription
 Canada

17. House(s) of congress and Federal agencies contacted Check if None


U. S. House
 U. S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Janie A. Kinney | |
| Sarah J. Walsh | |
| Patrick McLain | |
| William Schuyler | |
| Elizabeth York | |
| Kimberly A. Williams | |
| Philip Thevenet | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature



Date

August 13, 2003

Printed Name and Title

Sarah J. Walsh , Vice President, Federal Government Relations, Tax and Pharmaceuticals

LD-2 (REV. 6/98)

Page 3 c

Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

H.Con Res 6 Supporting the goals and ideals of the Chronic Obstructive Pulmonary Disease Awareness Month

17. House(s) of congress and Federal agencies contacted Check if None

U.S. House of Representatives


U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Janie A. Kinney | |
| Sarah J. Walsh | |
| Patrick McLain | |
| William Schuyler | |
| Elizabeth York | |
| Kimberly A. Williams | |
| Philip Thevenet | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature



Date August 13, 2003

Printed Name and Title

Sarah J. Walsh, Vice President, Federal Government Relations, Tax and Pharmaceutical
Filing #20fce1a1-e6fa-46ce-bbe8-8f8ddcc278dc - Page 7 of 14

Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S. 814 Bill to include Hepatitis A vaccines in the Vaccine Injury Compensation program under title XXI of the Health Service Act
 S. 847 Early Treatment for HIV Act of 2003

17. House(s) of congress and Federal agencies contacted Check if None

U. S. House of Representatives
 U. S. Senate
 Office of National AIDS Policy
 US Trade Representative

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Janie A. Kinney | |
| Sarah J. Walsh | |
| Patrick McLain | |
| William Schuyler | |
| Elizabeth York | |
| Kimberly A. Williams | |
| Philip Thevenet | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date August 13, 2003

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the client was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

- H.R. 2, S. 2 Jobs and Growth Tax Act of 2003
- H.R. 878 Armed Forces Tax Fairness Act of 2003
- H.R. 1674 Amend the Internal Revenue Code of 1986 to provide that the vaccine excise tax shall apply to any vaccine for Hepatitis A
- H.R. 865 Smallpox Vaccine Compensation and Safety Act of 2003
- S. 1054 Jobs and Growth Tax Relief Reconciliation Act of 2003

17. House(s) of congress and Federal agencies contacted Check if None

US House of Representative
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Janie Kinney | |
| Sarah J. Walsh | |
| Patrick McLain | |
| William Schuyler | |
| Elizabeth York | |
| Kimberly A. Williams | |
| Philip Thevenet | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature



Date

August 13, 2003

Printed Name and Title


Sarah J. Walsh, Vice President, Federal Government Relations, Tax and Pharmaceuticals

Date August 15, 2005

Registrant Name GlaxoSmithKline Client Name Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

| Name | Address | Principal Place of B (city and state or co |
|------|---------|---|
| | | |

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client


FOREIGN ENTITIES

27. Add the following foreign entities

| Name | Address | Principal place of business (city and state or country) | Amount of contribution for lobbying activities | (C pe |
|------|---------|--|---|----------|
| NONE | | | | |

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, client or affiliated organization

Signature



Date

August 13, 2003

Printed Name and Title

Sarah J. Walsh , Vice President, Federal Government Relations, Tax and Pharmaceuticals

LD-2 (REV. 6/98)

Page 7 of 7